Dansey, Roger

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Henry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V., Costa, L., Woll, P. J., Scagliotti, G., Smith, G., Feng, A., et al. (2014) · Supportive Care in Cancer

Bone health and treatmentsBone health and osteoporosis research

Cited by 183

Selection of a phase 3 dose regimen for denosumab based on pharmacokinetic (PK), pharmacodynamic (PD), and safety data from multiple subcutaneous (SC) dosing regimens in breast cancer patients (pts) with bone metastases (BM).

Peterson, M. C., Jang, G., Kim, W., Gurrola, E., Kinsey, A., & Dansey, R. (2006) · Journal of Clinical Oncology

Bone health and treatmentsBone health and osteoporosis research

Cited by 14